Fate Therapeutics (FATE) Research & Development (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Research & Development came in at $24.7 million in Q1 2026, down 15.21% YoY from $29.1 million in Q1 2025, and down 2.84% on a QoQ basis from $25.4 million in Q4 2025.
Fate Therapeutics (FATE) Research & Development (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Research & Development data on file, last reported at $24.7 million in Q1 2026.
- Quarterly Research & Development fell 15.21% year-over-year to $24.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103.4 million (down 21.67% YoY) and the FY2025 annual result came in at $107.8 million, down 20.13% from the prior year.
- Research & Development retreated to $24.7 million in Q1 2026, from $25.4 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $87.2 million in Q4 2022 to a low of $24.7 million in Q1 2026.
- A 5-year average of $44.7 million and a median of $34.3 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development jumped 69.31% — and 2023, when it slumped 63.51%.
- Tracing FATE's Research & Development over 5 years: stood at $87.2 million in 2022, then sank by 63.51% to $31.8 million in 2023, then advanced by 5.64% to $33.6 million in 2024, then dropped by 24.35% to $25.4 million in 2025, then slipped by 2.84% to $24.7 million in 2026.
- The last three Research & Development figures came in at $24.7 million (Q1 2026), $25.4 million (Q4 2025), and $25.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 24.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.70 Mn |
| Dec 31, 2025 | 25.43 Mn |
| Sep 30, 2025 | 25.84 Mn |
| Jun 30, 2025 | 27.43 Mn |
| Mar 31, 2025 | 29.14 Mn |
| Dec 31, 2024 | 33.61 Mn |
| Sep 30, 2024 | 34.65 Mn |
| Jun 30, 2024 | 34.60 Mn |
| Mar 31, 2024 | 32.14 Mn |
| Dec 31, 2023 | 31.82 Mn |
| Sep 30, 2023 | 34.28 Mn |
| Jun 30, 2023 | 40.88 Mn |
| Mar 31, 2023 | 65.63 Mn |
| Dec 31, 2022 | 87.19 Mn |
| Sep 30, 2022 | 79.82 Mn |
| Jun 30, 2022 | 81.31 Mn |
| Mar 31, 2022 | 72.14 Mn |
| Dec 31, 2021 | 69.52 Mn |
| Sep 30, 2021 | 53.13 Mn |
| Jun 30, 2021 | 48.02 Mn |